Seasonal Tailwind — july med 6.5% (mag 2/3) · posClose 64.29% (rel 1/3) · n14 ×1 = 6.3
Founder-Led — founder/CEO led
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-r… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Exchange: NASDAQ
IPO Date: May 1, 2012
Headquarters: 9715 Key West Avenue, Rockville, MD, United States, 20850
Founder-Led: Yes — Jack A. Khattar (President and Chief Executive Officer, Director)
Key Metrics
Current Price
$48.46
Market Cap
$2.83B
Float
52.1M
Shares Outstanding
58.0M
P/E (Forward)
20.16
Price/Sales (TTM)
3.64
vs. Analyst Target
+31.0% to analyst PT
Profit Margin
-3.74%
Operating Margin (TTM)
-3.58%
Revenue (TTM)
$777M
Earnings Growth (YoY)
11.10%
Dividend Rate
None
Analyst Target Price
$63.50 (5 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$520M
$127M
$468M
$211M
2021
$580M
$53.4M
$505M
$129M
2022
$667M
$60.7M
$580M
$153M
2023
$608M
$1.3M
$524M
$90.0M
2024
$662M
$73.9M
$584M
$178M
2025
$719M
-$38.5M
$644M
$42.5M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$165M
$22.5M
Sep 2025
$192M
-$45.1M
Dec 2025
$212M
-$4.1M
Mar 2026
$208M
-$2.3M
Ownership & Float
Insider Ownership
4.5%
Institutional Ownership
102.8%
Short Float
11.7%
% of All Funds Holding
3.65%
Number of Funds Holding
300
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$47.22
Near-term / short-term trend
Weekly
40-Week SMA
$49.09
Medium-term trend
Weekly
80-Week SMA
$42.68
Cyclical trend (business cycle)
Weekly
200-Week SMA
$36.47
Secular trend (multi-year)
Monthly
10-Month SMA
$49.41
Near-term monthly trend
Monthly
20-Month SMA
$42.86
Medium-term monthly trend
Monthly
40-Month SMA
$36.74
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$55.00
resistance
1.38x
7 months ago
$34.70
support
1.71x
10 months ago
$31.50
support
1.56x
11 months ago
$29.80
support
1.11x
22 months ago
$26.90
support
1.02x
23 months ago
Historical Earnings Reactions (57 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.37%
0.10%
54.39%
8.40%
-1.84%
1 Day
0.61%
0.81%
63.16%
7.42%
-4.82%
1 Week
0.16%
0.39%
54.39%
30.11%
-34.86%
2 Weeks
0.93%
0.45%
50.88%
29.91%
-27.42%
1 Month
3.26%
0.98%
53.57%
125.00%
-35.86%
Next earnings: August 4, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
5.4%
64.3%
14
Feb
-0.7%
50.0%
14
Mar
3.6%
50.0%
14
Apr
2.0%
57.1%
14
May
4.3%
50.0%
14
Jun
9.1%
66.7%
15
Jul
3.4%
64.3%
14
Aug
1.6%
57.1%
14
Sep
-2.3%
35.7%
14
Oct
-0.2%
50.0%
14
Nov
-0.6%
57.1%
14
Dec
-0.6%
50.0%
14
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.07%
48.6%
669
Tuesday
0.24%
51.4%
732
Wednesday
0.28%
54.9%
730
Thursday
-0.12%
47.7%
717
Friday
0.25%
52.3%
715
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 102.8%
Insider Transactions — Smart Summary
Total insider ownership: 4.5%
Founder-led management: Jack A. Khattar (President and Chief Executive Officer, Director)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Supernus Pharmaceuticals Inc
(SUPN) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.